These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15940953)

  • 21. [Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?].
    Pregun I; Herszényi L; Juhász M; Miheller P; Tulassay Z
    Orv Hetil; 2006 Mar; 147(10):435-9. PubMed ID: 16573172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
    Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Helicobacter pylori eradication in peptic dyspepsia.
    Lule GN
    East Afr Med J; 2005 Dec; 82(12):601-2. PubMed ID: 16619702
    [No Abstract]   [Full Text] [Related]  

  • 24. [Methods for increasing the efficacy and safety of Helicobacter pylori eradication regimens].
    Zakharova NV
    Eksp Klin Gastroenterol; 2006; (4):59-66. PubMed ID: 17269426
    [No Abstract]   [Full Text] [Related]  

  • 25. [PPI-test as a differential criterion of selection for gastroesophageal reflux disease surgery].
    Anishchenko VV; Shmakova EA
    Eksp Klin Gastroenterol; 2005; (4):59-66. PubMed ID: 16255540
    [No Abstract]   [Full Text] [Related]  

  • 26. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.
    Vergara M; Catalán M; Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1411-8. PubMed ID: 15948807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Leaving Helicobacter pylori no chance. Triple therapy should consider resistance status].
    MMW Fortschr Med; 2005 May; 147(20):52. PubMed ID: 15957863
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of reflux disease with proton pump inhibitors].
    Rösch W
    Pharm Unserer Zeit; 2005; 34(3):210-5. PubMed ID: 15940954
    [No Abstract]   [Full Text] [Related]  

  • 29. [Drugs in pregnancy. Treatment of duodenal ulcer].
    Schröder H
    Med Monatsschr Pharm; 2003 Jan; 26(1):23-4. PubMed ID: 12577793
    [No Abstract]   [Full Text] [Related]  

  • 30. Peptic ulcer disease.
    Louw JA
    Curr Opin Gastroenterol; 2006 Nov; 22(6):607-11. PubMed ID: 17053437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention and treatment of gastroduodenal hemorrhages in pediatric cardiac surgery].
    Khar'kin AV; Lobacheva GV; Manerova AF; Abramian MA; Savchenko MV
    Anesteziol Reanimatol; 2005; (1):38-41. PubMed ID: 15839223
    [No Abstract]   [Full Text] [Related]  

  • 32. Proton pump inhibitors to be used more?
    Andrawiss M
    Drug Discov Today; 2005 May; 10(9):607-8. PubMed ID: 15894221
    [No Abstract]   [Full Text] [Related]  

  • 33. The choice of a proton pump inhibitor.
    Schaffalitzky de Muckadell OB
    Basic Clin Pharmacol Toxicol; 2004 Mar; 94(3):105. PubMed ID: 15049338
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Nov; 39(11):1844-51. PubMed ID: 16204393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on peptic ulcer drugs.
    Aronson B
    Am J Nurs; 1998 Jan; 98(1):41-6. PubMed ID: 9455332
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacoeconomic aspects of the use of proton pump inhibitors].
    Lazebnik LB; Masharova AA; Guseĭnzade MG
    Eksp Klin Gastroenterol; 2006; (4):67-72. PubMed ID: 17269427
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug interactions between proton pump inhibitors and antiretroviral drugs.
    McCabe SM; Smith PF; Ma Q; Morse GD
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):197-207. PubMed ID: 17428151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug preparations of proton pump inhibitors].
    Breitkreutz J
    Pharm Unserer Zeit; 2005; 34(3):216-23. PubMed ID: 15940955
    [No Abstract]   [Full Text] [Related]  

  • 40. Proton pump inhibitors and the risk of colorectal cancer: a meta-analysis.
    Chen S; Song X; Gao X; Li M; Chen Z; He Y; Zhan W
    J Clin Gastroenterol; 2011 Feb; 45(2):177. PubMed ID: 20697292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.